Exact Sciences (EXAS) shares surged 20% as Abbott (ABT) announced a $21 billion acquisition. Each EXAS share will be bought for $105, a significant premium. The stock is up over 160% from its low in April. The market has priced in the deal, leaving little room for further gains. A competing bid is unlikely, making this deal the peak for shareholders.

UBS analysts believe a rival bid is improbable due to the unique fit Abbott offers. The end of EXAS’ partnership with Pfizer makes therapeutics companies unlikely suitors. Reference labs and product companies are potential buyers, but they have limitations. This acquisition is seen as the best outcome for Exact Sciences shareholders.

Abbott’s premium offer for EXAS validates its leadership in cancer screening. However, the risk-reward profile for new investors is unfavorable going into 2026. The deal solidifies Exact Sciences’ position in the market, but caution is advised for those considering entering the stock at current levels.

Read more at Yahoo Finance: Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?